Compare Moderna, Inc. (MRNA) vs Uranium Energy Corp (UEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Uranium Energy Corp — how do they compare? Moderna, Inc. trades at $63.47 (market cap $24.18B), while Uranium Energy Corp trades at $11.36 (market cap $5.67B). The key difference: Moderna, Inc. is far larger — about 4.3× Uranium Energy Corp's market cap, and Moderna, Inc. is trading nearer its 52-week high, Uranium Energy Corp nearer its low. Which is the better fit depends on your goals.
| MRNA | UEC | |
|---|---|---|
Market Cap | $24.18B | $5.67B |
Sector | Health | Energy |
52-Week High | $81.80 | $20.14 |
52-Week Low | $22.36 | $9.04 |
Enterprise Value | $20.33B | $5.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $63.70, up 6.5% recently, with a bullish technical signal and strong moving average support. Despite negative net income margins, the company beat Q2 2026 EPS estimates and secured FDA approval for its mRNA flu vaccine, mFLUSIVA, signaling diversification beyond COVID-19. Revenue has declined from pandemic peaks but is projected to stabilize around $2.2B in 2026.
The outlook is mixed: near-term catalysts from new vaccine approvals and pipeline progress offer upside, but persistent losses and high valuation multiples pose risks. Analyst consensus is cautious with a hold-heavy rating, reflecting uncertainty over profitability timelines amid ongoing R&D investments.
Uranium Energy Corp (UEC) trades at $11.45, up 0.62% today, with a bullish technical signal supported by moving averages. The company shows significant financial challenges with a net income margin of -513.24% and negative cash flow from operations, though it maintains strong analyst support with 87.5% buy ratings. Recent news highlights insider selling but also optimistic long-term nuclear energy prospects.
UEC presents high-risk, high-reward potential driven by nuclear energy tailwinds, but faces substantial execution risks amid persistent losses and premium valuation. The stock's outlook hinges on production ramp-up success and uranium price movements, with current financials indicating cautious near-term investor sentiment despite bullish analyst consensus.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Uranium Energy Corp
Uranium Energy Corp is a leading American uranium mining and exploration company, currently holding the largest resource base and licensed production capacity in the United States. Utilizing low-cost, environmentally friendly In-Situ Recovery (ISR) mining, UEC is a central player in the domestic nuclear fuel supply chain, transitioning from a resource holder to an active producer and refiner to meet the accelerating demand for carbon-free energy.
Read more on UEC →
